ArticleJAC-antimicrobial resistance2026
Clinical outcomes of dalbavancin versus standard therapy for non-severe skin and soft-tissue infections as well as bone and joint infections: a retrospective observational study.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The burden of bacterial infections, including skin and soft-tissue infections (SSTI) and bone and joint infections (BJI), is substantial. We aimed to assess clinical outcomes in non-severe cases of SSTI and BJI following dalbavancin treatment compared with those after other standard treatments. Methods: This retrospective observational study used the multicentre TriNetX electronic medical records database. Following propensity score matching (PSM), ORs with 95% CIs were estimated to compare hospitalization risk following dalbavancin administration relative to other antimicrobials. Results: Before PSM, 957 and 73 853 participants were identified in the dalbavancin and other standard treatment groups, respectively. After PSM, 957 patients remained in each cohort, with hospitalization observed in 167 (17.5%) and 239 (25.0%) participants in the dalbavancin and other standard treatment groups, respectively (OR 0.64 [95% CI 0.51-0.79]; Conclusions: Dalbavancin treatment was associated with significantly fewer hospitalizations than standard therapy in non-severe cases of SSTI and BJI. The results should be interpreted cautiously due to selection bias and potential unmeasured confounders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.